Investor Relations · March 20, 2024. Amicus Therapeutics Issues 2024 Environmental, Social, and Governance (ESG) Report · March 1, 2024. Amicus Therapeutics to ...
Galafold(migalastat) · Pombiliti + Opfolda(cipaglucosidase alfa-atga) ... Investors & Media. Investors & Media; Investor Relations · Corporate Governance ...
Get the latest insights on Amicus Therapeutics, Inc. Common Stock (FOLD) with press releases and corporate news to help you in your trading and investing ...
Get the latest Amicus Therapeutics, Inc. (FOLD) stock news and headlines to help you in your trading and investing decisions.
Missing: relations | Show results with:relations
Common Stock (FOLD) including earnings per share, earnings forecasts at Nasdaq ... Investor Relations Intelligence. Featured ... Common Stock (FOLD) Earnings. Data ...
See the company profile for Amicus Therapeutics, Inc. (FOLD) ... (FOLD) ... D. Chief Science Officer, --, --, --. Andrew Faughnan, Senior Director of Investor ...
The Investor Relations website contains information about McCormick & Company, Inc.'s business for stockholders, potential investors, and financial analysts ...
Mar 1, 2024 · ... FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in March. Cowen 44th ...
People also ask
How many employees does amicus Therapeutics have?
What is an investor relations website?
Feb 28, 2024 · For the full-year 2024, the Company anticipates total Galafold revenue growth between 11% and 16% at CER1 driven by continued underlying demand ...
Oct 2, 2023 · This strategic investment demonstrates Blackstone's commitment to Amicus' future and belief in the strong growth potential of Galafold and ...